The stock price performance for the year has been a mixed bag, indicating either a pessimistic or optimistic outlook depending on how you look at it. This year’s metric has recorded a Price decrease of -36.72%. However, over the past six months, we’ve seen a stronger performance of -40.73%. The price of ELEV fallen by 36.87% over the last 30 days. And in the last five days, it has fallen by -5.85%.
The market performance of Elevation Oncology Inc’s stock has been turbulent in recent times. Over the last year, the company’s stock reached its highest point at $4.48 on 05/01/24, while the lowest value for the same duration was $0.22 on 04/09/25.
52-week price history of ELEV Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Elevation Oncology Inc’s current trading price is -92.05% away from its 52-week high, while its distance from the 52-week low is 61.09%. The stock’s price range during this period has varied between$0.22 and $4.48. The Elevation Oncology Inc’s shares, which operate in the Healthcare, saw a trading volume of around 0.82 million for the day, a figure considerably lower than their average daily volume of 1.54 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Elevation Oncology Inc (ELEV) has experienced a quarterly decline of -41.23% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 21.08M and boasts a workforce of 34 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 0.5310, with a change in price of -0.2800. Similarly, Elevation Oncology Inc recorded 2,009,378 in trading volume during the last 100 days, posting a change of -44.03%.
ELEV’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for ELEV stands at 0.52. Similarly, the long-term debt-to-equity ratio is also 0.52.
ELEV Stock Stochastic Average
As of today, Elevation Oncology Inc’s raw stochastic average for the last 50 days stands at 27.06%. This is a decline compared to the raw stochastic average of the previous 20 days, which was noted at 77.19%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 84.03% and 86.68%, respectively.
